Getting Ready for the Bounce: Trevi Therapeutics Inc (TRVI) Stock

B. Riley Securities raised the price target for the Trevi Therapeutics Inc (NASDAQ:TRVI) stock to “a Buy”. The rating was released on April 12, 2023, according to finviz. The research report from SVB Leerink has initiated the stock to Outperform, with a price target set at $14. The stock was initiated by Stifel, who disclosed in a research note on June 03, 2019, to Buy and set the price objective to $20. In their research brief published June 03, 2019, Needham analysts initiated the Trevi Therapeutics Inc stock to Buy with a price target of $18.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -6.41% within the last five trades and 15.07% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 47.69% in the last 6 months and 141.73% was added to its value over the previous 3 months. TRVI stock is trading at a margin of 4.79%, 38.65% and 65.41% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


As of the close of trading, TRVI deals in the Healthcare domain. The stock is trading -16.00 percent below its 52-week high and 246.39 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 17.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Trevi Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $231.71 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 2.78, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 36.11 percent of Trevi Therapeutics Inc shares are owned by insiders, and 43.59 percent are held by financial institutions. Delfini Lisa, the Chief Financial Officer at Trevi Therapeutics Inc (TRVI) has sold 785 shares of firm on Oct 11 ’23 at a price of $2.02 against the total amount of $1586.0. In another inside trade, Delfini Lisa, Chief Financial Officer of Trevi Therapeutics Inc (NASDAQ:TRVI) sold 711 shares of the firm on Sep 11 ’23 for a total worth of $1564.0 at a price of $2.20. An inside trade which took place on Aug 11 ’23, Chief Financial Officer of Trevi Therapeutics Inc Delfini Lisa sold 682 shares of firm against total price of $1610.0 at the cost of $2.36 per share.

Most Popular

Related Posts